What is she best known for?
The fields of study she is best known for:
- Internal medicine
- Gene
- Immune system
Emma Guttman-Yassky spends much of her time researching Immunology, Atopic dermatitis, Psoriasis, Immune system and Filaggrin.
Her studies deal with areas such as Immunoglobulin E, Internal medicine, Disease and SCORAD as well as Atopic dermatitis.
Her Internal medicine research incorporates themes from Gastroenterology and Placebo.
Her research integrates issues of Tumor necrosis factor alpha, Cytokine, Inflammation, CCL17 and Keratin 16 in her study of Psoriasis.
Her Filaggrin study combines topics in areas such as Involucrin and FOXP3.
Her Eczema Area and Severity Index research is multidisciplinary, relying on both Dupilumab and Tralokinumab.
Her most cited work include:
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis (854 citations)
- Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. (786 citations)
- Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. (625 citations)
What are the main themes of her work throughout her whole career to date?
Her primary areas of study are Atopic dermatitis, Immunology, Dermatology, Immune system and Psoriasis.
Her Atopic dermatitis research integrates issues from Internal medicine, Disease and SCORAD.
Her Internal medicine study incorporates themes from Gastroenterology and Placebo.
Her Inflammation, Filaggrin, T cell, Immunoglobulin E and Cytokine study are her primary interests in Immunology.
Her Immune system study combines topics from a wide range of disciplines, such as Antigen and Pathogenesis, Pathology.
The study incorporates disciplines such as Tumor necrosis factor alpha, Transcriptome and Interleukin 17 in addition to Psoriasis.
She most often published in these fields:
- Atopic dermatitis (105.02%)
- Immunology (79.45%)
- Dermatology (34.02%)
What were the highlights of her more recent work (between 2020-2021)?
- Atopic dermatitis (105.02%)
- Immunology (79.45%)
- Dupilumab (18.95%)
In recent papers she was focusing on the following fields of study:
Her scientific interests lie mostly in Atopic dermatitis, Immunology, Dupilumab, Immune system and Dermatology.
Eczema Area and Severity Index is the focus of her Atopic dermatitis research.
Her Immunology research includes elements of Microbiome, Transcriptome and Personalized medicine.
As part of one scientific family, Emma Guttman-Yassky deals mainly with the area of Immune system, narrowing it down to issues related to the Pathogenesis, and often Immune tolerance.
Her research in Dermatology intersects with topics in Moderate to severe, Double blind study, Biomarker and Interleukin 17.
The concepts of her Psoriasis study are interwoven with issues in Dendritic cell, Human skin and Keratinocyte.
Between 2020 and 2021, her most popular works were:
- Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis (25 citations)
- Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis (25 citations)
- Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis. (24 citations)
In her most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Immune system
Emma Guttman-Yassky mainly investigates Atopic dermatitis, Internal medicine, Dupilumab, Dermatology and Eczema Area and Severity Index.
She interconnects Clinical trial, SCORAD, Placebo, Disease and Biomarker in the investigation of issues within Atopic dermatitis.
Her SCORAD research includes themes of Lebrikizumab, Immunology, Tralokinumab and Intensive care medicine.
Her work deals with themes such as Psoriasis, Clinical severity and Bioinformatics, which intersect with Biomarker.
Her study focuses on the intersection of Psoriasis and fields such as Fold change with connections in the field of Immune system.
Her work carried out in the field of Dermatology brings together such families of science as Double blind study and Interleukin 17.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
